A Phase I, Open Label, Multi-Center Study of TAS-109 Given by Continuous Intravenous 7-day Infusion in Patients with Advanced or Metastatic Solid Tumors.

Trial Profile

A Phase I, Open Label, Multi-Center Study of TAS-109 Given by Continuous Intravenous 7-day Infusion in Patients with Advanced or Metastatic Solid Tumors.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2009

At a glance

  • Drugs TAS 109 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 24 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top